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Summary
Over a three years period, 472 Candida isolates were 
obtained from specimens of patients hospitalized either in 
“at risk”, Bone Marrow Transplant Unit and Intensive Care 
Unit, or in conventional wards, Pneumological Divisions of 
the “Binaghi” Hospital of Cagliari (Italy). Antifungal suscep-
tibility profile to amphotericin B, voriconazole, fluconazole 
and ketoconazole was determined. Candida albicans was the 
predominant species while Candida krusei was the most fre-
quent non-albicans species. C. krusei was significantly more 
common among Bone Marrow Transplant Unit and Intensive 
Care Unit than Pneumological Divisions patients (17.9% 
and 14.1% vs. 6.0%; p < 0.05). No significant differences 
were observed when the same distribution was analysed with 
regard to the other Candida species or when Bone Marrow 
Transplant Unit and Intensive Care Unit were compared. The 
profiles of susceptibility to the antifungal drugs among iso-
lates from the different hospital wards showed no significant 
differences, even though most of MIC values were higher 
for Intensive Care Unit isolates compared to those for Bone 
Marrow Transplant Unit and Pneumological Divisions. For C. 
albicans isolates, amphotericin B was the more efficient anti-
fungal (97.7% S), while fluconazole (6.1% R [Resistant] and 
2.6% SDD [Susceptible Dose Dependent]) and ketoconazole 
(4.1% R and 3.2% SDD) showed the lowest activity. Vorico-
nazole was the more efficient antimycotic for C. krusei (96.7% 
S) and Candida glabrata (100% S [Sensible]) isolates.
This study has shown a significantly higher presence of non-
albicans Candida in at risk wards as well as a decreased sus-
ceptibility to the older azoles (ketoconazole and fluconazole) 
among C. albicans isolates.
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Introduction
in recent years, the genus Candida has became the 
principal cause of human yeast infections, with Candi-
da albicans being the most commonly isolated species, 
presumably for its capacity to reside in the natural flora 
of healthy individuals as a commensal organism.
an increasing incidence of infections, caused by 
species other than C. albicans, has been recently 
reported by several investigators [1-3]. the contribu-
tion of non-albicans species to fungemia has been 
summarized by Krcmery and Barnes [4] and Pfaller 
and diekema [2] who showed, among other things, 
that there are clear geographical differences in the 
distribution of Candida spp., other than C. albicans, 
causing invasive disease.
Sandven [5] reviewed that, in the United States, from 
1972 to 1998 the proportion of the most important 
non-albicans species has varied: in fact Candida 
tropicalis was prevalent in earlier studies while C. 
glabrata increased in the latter years.
More recent epidemiological data, coming from a study 
conducted in seven European countries by the Euro-
pean Confederation of Medical Mycology (ECMM), 
reported that C. glabrata was the second most com-
mon species in all the countries except in italy and 
Spain where C. parapsilosis was isolated with higher 
frequency [3].
Many are the suggested risk factors for infections with 
Candida species: other than impaired immunity for C. 
albicans, prophylaxis with azole compounds for C. kru-
sei and C. glabrata [6], neutropenia and bone marrow 
transplantation for C. tropicalis [7], low age, parenteral 
alimentation and intravascular device for C. parapsi-
losis [8, 9]. Recently, mucous membrane colonization 
has been demonstrated as a significant risk factor for 
candidemia in several biomolecular studies [10, 11].
a knowledge of the distribution and antifungal sus-
ceptibility of Candida species in patients hospital-
ized can be helpful in detecting epidemics, deciding 
empirical treatment regimes and selecting the right 
antimycotics [12].
this study was conducted to evaluate the distribution 
of Candida species and their antifungal susceptibility 
in patients hospitalized in three different types of ward 
of a single institution during a three years period.




Four hundred and seventy two Candida isolates, 
obtained from clinical specimens of patients hospital-
ized in Pneumological divisions (Pd), Bone Marrow 
transplant Unit (BMtU) and intensive Care Unit 
(iCU) of the “Binaghi” Hospital of Cagliari (Sardinia, 
italy) between april 2003 and april 2006, were in-
cluded in the study. More than one Candida isolate 
from a single patient was included if the specimen 
was obtained from separate body sites and/or at dif-
ferent time intervals, or if multiple Candida species 
were identified.
Surveillance cultures were performed twice weekly 
in iCU and once in pre-transplant period in BMtU. 
Specimens included five biological samples in iCU 
(bronchus fluid, pharingeal and nasal swabs, faeces or 
rettal swab and urine) and four in BMtU (pharingeal 
and nasal swabs, faeces or rettal swab and urine), 
respectively. Sputum was analyzed once a week on 
each patient admitted to Pd until discharge. in addi-
tion, biological samples were performed each time a 
candidiasis was suspected by physicians.
isolates were identified, in the hospital laboratory, by 
biochemical tests using aPi id 32 C (bioMerieux, St 
louis, Mo) as recommended by the manufacturer, and 
maintained at -20 °C in skim milk (oxoid, Basingstoke, 
UK) until the transfer to the university laboratory.
Prior to antifungal susceptibility testing, each isolate 
was subcultured on Sabouraud dextrose agar (Sda) 
(Microbiol, Cagliari, italy) for 24 h at 35 °C to ensure 
purity and viability and to confirm identification.
antifungal susceptibility testing
the susceptibility to antifungal drugs of Candida 
isolates was determined by using the broth microdilu-
tion method described by the Clinical and laboratory 
Standards institute (ClSi), document M27-a2 [13]. 
the following antifungal drugs, as pure standard com-
pounds, were tested: amphotericin B (Sigma, S. louis, 
Missouri, USa), voriconazole and fluconazole (Pfizer 
Pharmaceuticals Group, new York, USa), ketocona-
zole (Sigma).
amphotericin B and ketoconazole final concentra-
tions ranged from 0.003 to 16 µg/ml, voriconazole 
from 0.015 to 16 µg/ml and fluconazole from 0.125 
to 128 µg/ml. MiCs (Minimum inhibbitory Con-
Tab. I. distribution of 472 Candida spp. grouped according to the biological site and the hospital ward. pd (pneumological division), BmTU 
(Bone marrow Transplant Unit), ICU (Intensive Care Unit).
Biological C. albicans C. krusei C. glabrata C. parapsilosis C. tropicalis Other species Total
sample PD BMTU ICU PD BMTU ICU PD BMTU ICU PD BMTU ICU PD BMTU ICU PD BMTU ICU
Sputum 64 12 5 3 1 4 1 4 1 95
Bronchus 
fluid 23 1 48 3 15 1 3 1 5 1 101
pharingeal 
swab 6 23 50 10 8 2 1 2 10 1 4 117
Tongue 
swab 13 3 1 1 18
Nasal 
swab 13 3 1 17
Faeces 16 14 6 3 2 1 1 43
Urine 4 35 1 1 2 1 7 1 2 1 55
Blood 1 3 1 1 1 1 8
vascular 8 4 2 14
catheter
Other sites 1 2 1 4
Total strains 343 61 22 21 15 10 472
Other species: C. sake (4 isolates), C. dubliniensis (3 isolates), C. kefir, C. pelliculosa and C. pseudotropicalis (each 1 isolate). Other sites: vaginal and 
skin swabs
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centrations) were determined visually at 48 h by 
comparison with the drug-free growth control well.
MiC interpretative criteria for fluconazole and vorico-
nazole were those proposed by the ClSi and recently 
published by Pfaller et al. [14, 15]: fluconazole (S: MiC 
≤ 8 µg/ml, SDD: MIC 16 to 32 µg/ml, R: MIC ≥ 64 
µg/ml), voriconazole (S ≤ 1 µg/ml, SDD 2 µg/ml, R ≥ 
4 µg/ml). due to a lack of interpretative criteria for am-
photericin B and ketoconazole, values were established 
according to previous studies [16-18] and were as fol-
lows: S ≤ 1 µg/ml and R ≥ 2 µg/ml for amphotericin B, 
S ≤ 0.125 µg/ml, SDD 0.25 and 0.50 µg/ml, R ≥ 1 µg/ml 
for ketoconazole.
C. krusei (atCC 6258) and C. parapsilosis (atCC 
22019) were included as quality control strains and MiCs 
were within the recommended range for each test [19].
statistical analysis
the statistical significance of the differences between 
the study groups was determined by the chi-square test. 
all comparisons were considered statistically signifi-
cant for P values of 0.05 or less.
Results
during the 3-year study period, 472 Candida spp. iso-
lates were recovered from the cultures of 255 patients 
submitted to the hospital laboratory and distributed 
as follows: 117 strains from Pd, 106 from BMtU 
and 249 from iCU patients. the strains investigated 
included isolates from patients receiving antifungal 
























amphotericin B 98 0.25/0.5 68 0.5/1 177 0.5/1 97.7 / 2.3
voriconazole 0.015/0.06 0.125/1 0.25/1 94.8 5.2 0
fluconazole 0.25/8 0.25/4 0.25/32 91.3 2.6 6.1
ketoconazole 0.03/0.125 0.03/0.06 0.03/0.125 92.7 3.2 4.1
C. krusei (61) amphotericin B 7 0.25/1 19 1/2 35 1/4 86.9 / 13.1
voriconazole 0.03/0.06 0.03/0.06 0.06/0.125 96.7 / 3.3
fluconazole 32/ > 64 16/32 16/ > 64 8.2 62.3 29.5
ketoconazole 0.25/1 0.5/2 0.5/2 18.0 65.6 16.4
C. glabrata (22) amphotericin B 3 1/- 7 0.5/1 12 0.5/1 95.5 / 4.5
voriconazole 0.5/- 0.5/0.5 0.5/0.5 100 / 0
fluconazole 2/- 0.25/4 4/32 77.3 13.6 9.1
ketoconazole 0.03/- 0.06/0.125 0.06/0.5 68.2 18.2 13.6
C. parapsilosis 
(21)
amphotericin B 1 0.25/- 4 0.25/1 16 0.06/1 100 / 0
voriconazole 0.06/- 0.06/0.125 0.06/0.125 100 / 0
fluconazole 1/- 1/2 1/2 100 0 0
ketoconazole 0.06/- 0.03/0.06 0.03/0.06 100 0 0
C. tropicalis 
(15)
amphotericin B 7 0.06/0.25 2 0.25/- 6 0.25/1 100 / 0
voriconazole 0.06/0.125 0.125/- 0.125/1 100 / 0
fluconazole 1/2 1/- 1/8 100 0 0
ketoconazole 0.03/0.03 0.03/- 0.03/0.125 100 0 0
* = the mIC90 value was not included when the number of strains was ≤ 3
m.e. FAddA eT AL.
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prophylaxis and patients without prophylaxis as well 
as isolates from infection and colonization.
the distribution of Candida species in each hospital 
ward and in the biological cultures is summarized in 
table i. overall, 343 (72.7%) isolates were identified 
as C. albicans. among other Candida species (27.3%), 
the most common was C. krusei (12.9%), followed 
by C. glabrata (4.7%), C. parapsilosis (4.4%) and C. 
tropicalis (3.2%). other Candida species, sporadically 
recovered (2.1%) included 4 C. sake, 3 C. dubliniensis 
and one each of C. pelliculosa, C. pseudotropicalis and 
C. kefir strains.
non-albicans Candida presence was significantly higher 
in BMtU (35.8%; p = 0.005) and iCU (28.9%; p = 0.01) 
compared to Pd (16.23%) patients. C. krusei was sig-
nificantly more common among BMtU and iCU than 
Pd patients (17.9% and 14.1% vs. 6.0%; p < 0.05).
no significant differences were observed when the 
same distribution was analysed with regard to the other 
Candida species or when comparing BMtU and iCU 
patients.
the profiles of susceptibility to amphotericin B, 
voriconazole, fluconazole and ketoconazole among the 
prevalent Candida species isolates, grouped according 
to the hospital ward, are compared in table ii. MiCs 
(µg/ml) at which 50% (MiC50) and 90% (MiC90) of 
the strains were inhibited as well as the percentages of 
susceptible, susceptible-dose dependent (for voricona-
zole, fluconazole, ketoconazole) and resistant strains 
were reported.
C. parapsilosis and C. tropicalis isolates were suscep-
tible to all agents examined. the profiles of suscepti-
bility to the antifungal drugs among isolates from the 
different hospital wards showed no significant differ-
ences, even though higher MiC values for iCU isolates 
compared to those for BMtU and Pd were obtained.
For C. albicans isolates, amphotericin B was the most 
efficient antifungal (97.7% S), while fluconazole 
(6.1% R and 2.6% Sdd) and ketoconazole (4.1% R 
and 3.2% Sdd) showed the lowest activity. no C. al-
bicans strains resistant to voriconazole were observed 
but 18 (5.2%) strains showed lowered susceptibility to 
this drug and the highest values of MiC50 and MiC90 
were detected in iCU and BMtU isolates.
Voriconazole was the more efficient antimycotic for C. 
krusei (96.7% S) and C. glabrata (100% S) isolates. C. 
krusei showed a high level of resistance to fluconazole 
and ketoconazole (91.8% and 82% between Sdd and 
R strains, respectively), and decreased susceptibility to 
fluconazole and ketoconazole was demonstrated in C. 
glabrata isolates, with 36.4% and 40.9% of Sdd and 
31.8% and 27.2% of R strains, respectively.
Discussion
Hospital acquired infections due to fungi still present 
formidable problems in terms of their diagnosis and 
even more so in terms of therapy. therefore, preven-
tion is a very important strategy in controlling these 
diseases. among the preventive measures, epidemio-
logical surveys are needed to better characterize the 
species distribution and the antifungal susceptibility 
profile of isolates because it is known that the epi-
demiology of infections in one institution may differ 
greatly from the epidemiology in another.
We focused our study on the number of isolates 
of Candida spp., during a period of three years, in 
patients hospitalized either in “at risk” (BMtU and 
iCU) or conventional (Pd) wards. although many 
studies were conducted to provide epidemiological 
information on the frequency and susceptibility pro-
file of different species of Candida isolates in blood-
stream infections [3, 20, 21], few data concerning the 
distribution of yeast species isolated from various 
body sites and in different areas of the same hospital 
are available in the literature.
in our study the total number of strains isolated in the 
hospital laboratory was taken into account without 
distinction between colonization and infection. in 
fact, several studies indicate colonization by Candida 
species as a prerequisite for the development of can-
didiasis both in immunosuppressed and non-neutro-
penic patients [22, 23].
in the present study, it is not surprising that C. albicans 
was the most common species isolated in all the wards, 
but we found troubling the significantly higher presence 
of non-albicans Candida species, and in particular C. 
krusei and C. glabrata, in “at risk” wards compared to 
conventional ward, although the role of these species 
as emergent pathogens in iCU and BMtU has recently 
been pointed out. trick et al. [21] described a signifi-
cant increase in incidence of bloodstream infections 
associated with C. glabrata among iCU patients in the 
United States during 1989-1999. C. albicans, followed 
by C. glabrata and C. krusei, was the most frequently 
isolated species in urine specimens of patients with 
indwelling urinary catheters in the iCU of “Sao Paulo” 
hospital, Brasil [24]. Safdar et al. [25] reported C. gla-
brata and C. krusei, as the most common yeast species 
responsible for hematogenous candidiasis in patients 
undergoing allogenic BMt during 1997-1999.
the high presence of C. krusei obtained in our study 
differs from data published in other studies. Even if 
the estimates of C. krusei isolation vary between in-
stitutions and over different years, it has been rarely 
encountered as responsible for infections. a recent 
ECMM multi-istitutional survey of Candida blood-
stream infections performed in Europe, reported a 
limited role of C. krusei with an isolation average of 
1.9% [3]. the same rate was reported by SEntRY 
antimicrobial Surveillance Program in north amer-
ica, Europe and latin america medical centres [26]. 
However, the rates of C. krusei are higher in studies 
concerning units with neutropenic or highly immuno-
compromised patients. Safdar [25] reported, among 
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15 episodes of candidemia after high-risk allogenic 
marrow transplantion, C. glabrata as the most com-
mon species (53.3%), followed by C. krusei (33.3%) 
and C. parapsilosis (13.3%) while C. albicans was 
absent. Krcmery and Barnes [4] reviewed that C. 
krusei occurred more frequently in leukaemic patients 
and bone marrow transplant recipients. Moreover, C. 
krusei was associated with a high mortality rate in 
several types of patients [27-29].
the particularly high incidence of C. krusei in this 
study, mainly in “high risk” wards, may be due to 
its presence among the species colonizing the upper 
and lower respiratory and orointestinal tracts [30]. 
at the same time, an exogenous infection related to 
invasive procedure or a selection of less susceptible 
species by an overuse of antifungal agents could be 
hypothesized.
antimicrobial resistances are generally more common 
in at risk than in conventional wards and our results 
support, in part, this fact as iCU isolates showed the 
highest MiCs, even if no significant difference was 
observed between the rate of resistant strains among 
the iCU and BMtU compared to Pd.
amphotericin B was the most active antifungal drug 
against C. albicans, although the overall resistance 
rate (2.3%) is higher than that reported in italy [31] 
and in other countries [32, 33].
in our study a decreased susceptibility to fluconazole 
and ketoconazole was observed in C. albicans isolates 
and, among non-albicans Candida, C. krusei and C. 
glabrata had the highest MiCs to these drugs. Moreo-
ver, higher MiCs for voriconazole were detected in 
strains of C. albicans with decreased susceptibility 
to fluconazole, while no correspondence between 
resistance to fluconazole and voriconazole has been 
found in C. glabrata and C. krusei strains. these data 
support, in part, the possibility of cross-resistance be-
tween fluconazole and voriconazole, as hypothesized 
by other authors [32, 34], and certainly they confirm 
the previously reported favorable in vitro activity of 
voriconazole against isolates with decreased suscep-
tibility to fluconazole [19].
Conclusions
this study has shown a significantly higher presence 
of non-albicans Candida species, in particular C. 
krusei and C. glabrata, in at risk wards as well as a 
relatively decreased susceptibility to the older azole 
drugs (ketoconazole and fluconazole) among C. albi-
cans isolates.
despite the limitations of this study, that include the 
lack of data about antifungal use in the hospital wards 
and of detailed clinical information for individual pa-
tients, we retain that the routine surveillance cultures 
provide a prevention of invasive candidiasis mainly 
guiding initiation of preemptive antifungal therapy in 
critically ill patients.
Further studies are in progress in order to identify 
possible changes in the species distribution, to assay 
the real rate of Candida infections and to better estab-
lish the correlation between the type of resistance and 
the patterns of usage of antifungal agents.
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